Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783467 | 0.82 | MEN1 (0.58) | MEN1RAB9AKMT2ANPC1LMNA | |
| SCHEMBL7978716 | 0.81 | STAT3 (0.59) | MEN1RAB9AKMT2ANPC1LMNA | |
| SCHEMBL4894832 | 0.79 | ATG4B (0.55) | MEN1RAB9AKMT2ANPC1LMNA | |
| SCHEMBL3256497 | 0.76 | AKT1 (0.48) | AKT1ALDH1A1FFAR4GAB1 | |
| SCHEMBL3256711 | 0.76 | AKT1 (0.56) | AKT1ALDH1A1FFAR4GAB1 | |
| SCHEMBL3253214 | 0.74 | AKT1 (0.46) | AKT1FFAR4GAB1 | |
| SCHEMBL3251192 | 0.73 | AKT1 (0.48) | AKT1ALDH1A1SMN1; SMN2FFAR4GAB1 | |
| SCHEMBL3256635 | 0.73 | AKT1 (0.51) | AKT1MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL3248288 | 0.72 | AKT1 (0.45) | AKT1ALDH1A1FFAR4GAB1 | |
| SCHEMBL3251447 | 0.72 | AKT1 (0.45) | AKT1FFAR4GAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001090093-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | claimed |
| US-20080033046-A1 | Treatment of myocardial infarction with 11HSD1 inhibitors | UNIVERSITY OF EDINBURGH (GB) | 2008-02-07 | — | — | US | disclosed |
| WO-2001090093-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033046-A1 | Treatment of myocardial infarction with 11HSD1 inhibitors | HSD11B1, HSD11B2, CYP11B1 | AKT1 2577/4885MEN1 2830/4885RAB9A 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.